CIK 0001404644 · Non-accelerated filer<br>Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 980542593
- Phone
- (877) 237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-13 | McMinn Rachel Chief Executive Officer | Grant or award · Employee Stock Option (Right to buy) | +93,282 | 93,282 | ||
| 2024-03-13 | Cvijic Christine Mikail President and CFO | Grant or award | +31,903 | 52,844 | ||
| 2024-03-13 | Cvijic Christine Mikail President and CFO | Grant or award · Employee Stock Option (Right to buy) | +53,900 | 53,900 | ||
| 2024-03-13 | Cobb Stuart Chief Scientific Officer | Grant or award | +20,391 | 20,391 | ||
| 2024-03-13 | Cobb Stuart Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +34,450 | 34,450 | ||
| 2024-01-16 | Woods Keith Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | Woods Robert Keith Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | PALEKAR ROHAN Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | Noonberg Sarah B. Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | Freedland Cory S. Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | BAFFI ROBERT Director | Grant or award · Stock Option (Right to Buy) | +15,400 | 15,400 | ||
| 2024-01-16 | Jordan Julie Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +78,325 | 78,325 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +973,290 | 973,290 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +28,782 | 107,107 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +310,130 | 1,283,420 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +20,562 | 127,669 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +221,557 | 1,504,977 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +93,480 | 221,149 | ||
| 2023-12-18 | BAKER BROS. ADVISORS LP Director | Grant or award · Prefunded Warrants | +1,151,124 | 2,656,101 |
Page 4 of 8 · 158 trades